NovoCure Limited
NVCR
$12.43
$0.524.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 158.81M | 154.99M | 161.27M | 155.10M | 150.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 158.81M | 154.99M | 161.27M | 155.10M | 150.36M |
| Cost of Revenue | 41.47M | 38.52M | 32.51M | 35.37M | 34.65M |
| Gross Profit | 117.33M | 116.47M | 128.75M | 119.72M | 115.70M |
| SG&A Expenses | 101.02M | 100.56M | 139.89M | 99.93M | 94.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.33M | 192.86M | 223.62M | 187.19M | 183.94M |
| Operating Income | -39.52M | -37.87M | -62.35M | -32.09M | -33.58M |
| Income Before Tax | -34.98M | -30.30M | -55.21M | -21.59M | -22.73M |
| Income Tax Expenses | 5.16M | 4.02M | 10.72M | 8.99M | 10.65M |
| Earnings from Continuing Operations | -40.14M | -34.32M | -65.92M | -30.57M | -33.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.14M | -34.32M | -65.92M | -30.57M | -33.38M |
| EBIT | -39.52M | -37.87M | -62.35M | -32.09M | -33.58M |
| EBITDA | -36.08M | -34.54M | -60.62M | -29.63M | -30.72M |
| EPS Basic | -0.36 | -0.31 | -0.61 | -0.28 | -0.31 |
| Normalized Basic EPS | -0.20 | -0.17 | -0.47 | -0.12 | -0.14 |
| EPS Diluted | -0.36 | -0.31 | -0.61 | -0.28 | -0.31 |
| Normalized Diluted EPS | -0.20 | -0.17 | -0.47 | -0.12 | -0.14 |
| Average Basic Shares Outstanding | 111.57M | 110.28M | 108.47M | 108.25M | 107.70M |
| Average Diluted Shares Outstanding | 111.57M | 110.28M | 108.47M | 108.25M | 107.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |